Pherecydes Pharma Selected for the French Tech Health20 Program’s 2023 Class
27 March 2023
Pherecydes Pharma a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announces that it has been selected for the 2023 French Tech Health20 program.
French Tech Health20 program aims to create French technological champions offering disruptive innovations in the health sector. The program supports start-ups in line with the Health Innovation 2030 governmental plan and in partnership with the Health Innovation Agency (Agence de l’Innovation en Santé - AIS) within the framework of its mission to support innovative companies in the field of health and covers various domains such as:
- bioproduction of innovative therapies;
- innovative medical devices;
- digital health;
- infectious and emerging diseases.
The selection conditions for the class of 2023 were particularly demanding, an independent jury of leading figures having selected the winners from almost 400 health companies. The 20 winning start-ups thus offer innovations, in terms of services and products, with a high degree of differentiation compared to existing solutions and have the potential for large-scale deployment.
By being in this first class of the program, Pherecydes Pharma will benefit from dedicated support from “French Tech correspondents” within public administrations and from experts within the Ministry of Health and Prevention, as well as the opportunity to participate in certain economic diplomacy actions and visibility campaigns.
Thibaut du Fayet, CEO of Pherecydes Pharma, said: “Pherecydes Pharma’s selection for the French Tech Health20 program rewards the efforts undertaken by our teams and recognizes our role in the development of the phage therapy field in France, considered to be a strategic technology on a European level. Our goal is to develop effective treatments for resistant bacterial infections, and I am convinced that our inclusion in the Health20 program is a real asset for the ramping up of our projects”.